Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 2014

View Archived Issues

Alzheimer's disease organizations fund drug repurposing studies

Scientists at M2i Development disclose novel diagnostic agents

Array BioPharma grants Oncothyreon exclusive license to ONT-380

Galapagos selects GLPG-2222 as part of its triple combination therapy for cystic fibrosis

Alnylam initiates phase III trial of revusiran in transthyretin-mediated amyloidotic cardiomyopathy

Novel JAK2 inhibitor NVP-CHZ868 displays potent activity in vitro and in murine MPN models

Hutchison MediPharma initiates phase III trial of fruquintinib in colorectal cancer

Inhibition of EZH2 leads to tumor growth inhibition in B-cell lymphoma cell lines

Study describes levels of biomarker of brain insulin resistance in hippocampal regions

Animal model of osteochondromagenesis highlights role of NFATc1

Kolltan Pharmaceuticals describes anti-SCFR monoclonal antibody

Antitumor activity seen with HER2-T-cell-dependent bispecific antibody developed at Genentech

BioCryst begins phase I trial of BCX-4430 for hemorrhagic fever viruses

Synageva BioPharma confirms active IND application for SBC-103

Novel CXCR-7 modulators disclosed by Actelion Pharmaceuticals

Cephalon divulges novel ALK inhibitors for cancer

Taiho Pharmaceutical patents novel compounds for urinary incontinence

Teijin Pharma reports new XO inhibitors

New company BliNK Biomedical created to focus on antibody discovery

Anthera Pharmaceuticals licenses Japanese rights to blisibimod to Zenyaku Kogyo

New study evaluates dabigatran etexilate to prevent recurrent embolic stroke of undetermined source

NEOD-001 given FDA fast track designation for AL amyloidosis

IND accepted for ADXS-HPV plus MEDI-4736 in HPV-associated cancers

Neovacs' phase IIb trial of TNF-Kinoid in rheumatoid arthritis misses endpoint

FDA approves Signifor LAR for acromegaly

ViiV Healthcare applies for Japanese approval of dolutegravir/abacavir/lamivudine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...